Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arcus Biosciences, Inc.

Latest From Arcus Biosciences, Inc.

Roche’s Data Leak Reawakens Hopes For TIGIT Lung Cancer Drug

An “inadvertent disclosure” of data has done Roche’s share price no harm, but analysts are still unsure that its TIGIT immunotherapy can prove a threat to Merck’s all-conquering Keytruda.

Clinical Trials Commercial

Merck’s Welireg Could Expand Into Broader Kidney Cancer Indication With Phase III Data

The drug maker announced Phase III results for the HIF-2α inhibitor in renal cell carcinoma patients with disease progression following PD-1/PD-L1 and anti-VEGF therapy.

Clinical Trials Cancer

Gilead’s Trodelvy May Have Safety Edge Due To Lack Of Concerning Lung Toxicity

Executives said there had been no cases of interstitial lung disease, while ILD – including fatal events – has become a potential problem for AstraZeneca/Daiichi Sankyo’s dato-DXd.

Sales & Earnings Cancer

Novartis Says No To TIGIT, Backs Out Of BeiGene Deal

Novartis declined to option BeiGene’s TIGIT inhibitor, ociperlimab. BeiGene will continue a Phase III study combining it with PD-1 inhibitor tislelizumab while dropping another Phase III.

Cancer Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies